Noopept vs PE-22-28
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Noopept
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide-derived nootropic developed in Russia. While technically a dipeptide prodrug rather than a true peptide, it's often discussed alongside peptide nootropics.
Full details →PE-22-28
PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.
Full details →Side-by-Side Comparison
| Aspect | Noopept | PE-22-28 |
|---|---|---|
| Mechanism | Metabolized to cycloprolylglycine which modulates AMPA and NMDA receptors, increases NGF and BDNF expression, and provides neuroprotective effects through antioxidant mechanisms. | Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways. |
| Typical Dosage | Oral: 10-30mg daily, typically divided into 2-3 doses. Sublingual use may enhance absorption. Some users go higher but effects may plateau. | Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established. |
| Administration | Oral or sublingual administration. Unlike most peptides, it's orally bioavailable. Can be taken with or without food. | Intranasal administration preferred for CNS delivery. Research compound with limited human use data. |
| Side Effects | Headache (often from choline depletion), irritability, insomnia if taken late, and occasional brain fog during initial use. | Very limited human data. Primarily studied in animal models for safety and efficacy. |
| Best For |
What They Have in Common
Both Noopept and PE-22-28 are commonly used for: